Splenectomy effects on chemotherapy in Hodgkin's disease.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D005069:Evaluation Studies as Topic; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013156:Splenectomy; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001565:Benzoates; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone